Literature DB >> 24035251

17 and 23: prime numbers for ankylosing spondylitis?

Robert A Colbert1, Michael M Ward.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24035251      PMCID： PMC3857094          DOI： 10.1016/S0140-6736(13)61913-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  17 in total

1.  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Authors:  Wolfgang Hueber; Bruce E Sands; Steve Lewitzky; Marc Vandemeulebroecke; Walter Reinisch; Peter D R Higgins; Jan Wehkamp; Brian G Feagan; Michael D Yao; Marek Karczewski; Jacek Karczewski; Nicole Pezous; Stephan Bek; Gerard Bruin; Bjoern Mellgard; Claudia Berger; Marco Londei; Arthur P Bertolino; Gervais Tougas; Simon P L Travis
Journal:  Gut       Date:  2012-05-17       Impact factor: 23.059

2.  Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials.

Authors:  Andrew D Dick; Ilknur Tugal-Tutkun; Stephen Foster; Manfred Zierhut; S H Melissa Liew; Vladimir Bezlyak; Sofia Androudi
Journal:  Ophthalmology       Date:  2013-01-03       Impact factor: 12.079

3.  Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.

Authors:  Mark C Genovese; Patrick Durez; Hanno B Richards; Jerzy Supronik; Eva Dokoupilova; Vadim Mazurov; Jacob A Aelion; Sang-Heon Lee; Christine E Codding; Herbert Kellner; Takashi Ikawa; Sophie Hugot; Shephard Mpofu
Journal:  Ann Rheum Dis       Date:  2012-06-23       Impact factor: 19.103

Review 4.  Developments in therapies for spondyloarthritis.

Authors:  Joachim Sieper
Journal:  Nat Rev Rheumatol       Date:  2012-04-10       Impact factor: 20.543

5.  The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis.

Authors:  Nigil Haroon; Robert D Inman; Thomas J Learch; Michael H Weisman; MinJae Lee; Mohammad H Rahbar; Michael M Ward; John D Reveille; Lianne S Gensler
Journal:  Arthritis Rheum       Date:  2013-10

6.  In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis.

Authors:  Heiner Appel; Rene Maier; Janine Bleil; Axel Hempfing; Christoph Loddenkemper; Uwe Schlichting; Uta Syrbe; Joachim Sieper
Journal:  Arthritis Rheum       Date:  2013-06

7.  Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.

Authors:  John C Davis; Désirée Van Der Heijde; Jurgen Braun; Maxime Dougados; John Cush; Daniel O Clegg; Alan Kivitz; Roy Fleischmann; Robert Inman; Wayne Tsuji
Journal:  Arthritis Rheum       Date:  2003-11

8.  IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells.

Authors:  Jonathan P Sherlock; Barbara Joyce-Shaikh; Scott P Turner; Cheng-Chi Chao; Manjiri Sathe; Jeff Grein; Daniel M Gorman; Edward P Bowman; Terrill K McClanahan; Jennifer H Yearley; Gérard Eberl; Christopher D Buckley; Robert A Kastelein; Robert H Pierce; Drake M Laface; Daniel J Cua
Journal:  Nat Med       Date:  2012-07-01       Impact factor: 53.440

9.  Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.

Authors:  Dominique Baeten; Xenofon Baraliakos; Jürgen Braun; Joachim Sieper; Paul Emery; Désirée van der Heijde; Iain McInnes; Jacob M van Laar; Robert Landewé; Paul Wordsworth; Jürgen Wollenhaupt; Herbert Kellner; Jacqueline Paramarta; Jiawei Wei; Arndt Brachat; Stephan Bek; Didier Laurent; Yali Li; Ying A Wang; Arthur P Bertolino; Sandro Gsteiger; Andrew M Wright; Wolfgang Hueber
Journal:  Lancet       Date:  2013-09-13       Impact factor: 79.321

10.  Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.

Authors:  Iain B McInnes; Joachim Sieper; Jürgen Braun; Paul Emery; Désirée van der Heijde; John D Isaacs; Georg Dahmen; Jürgen Wollenhaupt; Hendrik Schulze-Koops; Joseph Kogan; Shenglin Ma; Martin M Schumacher; Arthur P Bertolino; Wolfgang Hueber; Paul P Tak
Journal:  Ann Rheum Dis       Date:  2013-01-29       Impact factor: 19.103
View more
  2 in total

Review 1.  Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond.

Authors:  Judith A Smith; Robert A Colbert
Journal:  Arthritis Rheumatol       Date:  2014-02       Impact factor: 10.995

Review 2.  Mechanistic rationales for targeting interleukin-17A in spondyloarthritis.

Authors:  Siba P Raychaudhuri; Smriti K Raychaudhuri
Journal:  Arthritis Res Ther       Date:  2017-03-08       Impact factor: 5.156
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.